NK-102 (Nara Biosciences)

N/A

Report date: 2025/07/09 20:00:48

Base Information

Drug NameNK-102 (Nara Biosciences)
Drug Alias Namemyokine (Nara Biosciences)NK-102
ClassificationBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsObesityDiabetes MellitusCarcinoma, Non-Small-Cell Lung +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBoston University
China Registration ClassN/A

Develop Information

Active CompaniesUniversity of California Irvine
Inactive CompaniesNara Biosciences IncBoston University
Active IndicationsCarcinoma, Non-Small-Cell LungLung Neoplasms
Inactive IndicationsObesityDiabetes Mellitus

Other Information

ATC CodeN/A
Related LinksN/A